{"abstract": "Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis.", "web_url": "https://www.nytimes.com/2007/01/24/business/24rash.html", "snippet": "Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis.", "lead_paragraph": " Are biotechnology companies reaching the limits of how much they can charge for their drugs? One sign of that is the sluggish sales of drugs for psoriasis. ", "print_section": "C", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2007/01/24/business/24rash1_600.jpg", "height": 300, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2007/01/24/business/24rash1_600.jpg", "xlargewidth": 600, "xlargeheight": 300}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2007/01/24/business/24rash1_75.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2007/01/24/business/24rash1_75.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "Biotech Psoriasis Drugs Hit a Cost Ceiling", "kicker": null, "content_kicker": null, "print_headline": "Biotech Psoriasis Drugs Hit a Cost Ceiling", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Biogen Idec Incorporated", "rank": 1, "major": "N"}, {"name": "subject", "value": "Skin", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AMGEN INC", "rank": 4, "major": "N"}, {"name": "subject", "value": "Medicine and Health", "rank": 5, "major": "N"}, {"name": "organizations", "value": "Genentech Inc", "rank": 6, "major": "N"}, {"name": "subject", "value": "Biotechnology", "rank": 7, "major": "N"}], "pub_date": "2007-01-24T05:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Andrew Pollack", "person": [{"firstname": "Andrew", "middlename": null, "lastname": "Pollack", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/82e260d8-ef6f-5427-8b40-cb39236326bf", "word_count": 1472, "uri": "nyt://article/82e260d8-ef6f-5427-8b40-cb39236326bf"}